Novo Nordisk cuts 9,000 jobs amid Ozempic competition
Danish pharmaceutical giant Novo Nordisk announces major restructuring, cutting 9,000 jobs globally. The move comes as competition intensifies in the lucrative weight-loss and diabetes drug market, challenging its blockbuster medications Ozempic and Wegov